A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint
Company to discontinue study, review full data set, and evaluate next steps for the program
https://www.globenewswire.com/news-release/2024/11/15/2981887/0/en/Eyenovia-Provides-Update-on-Phase-3-CHAPERONE-Study.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.